ECSP22003665A - Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll - Google Patents

Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll

Info

Publication number
ECSP22003665A
ECSP22003665A ECSENADI20223665A ECDI202203665A ECSP22003665A EC SP22003665 A ECSP22003665 A EC SP22003665A EC SENADI20223665 A ECSENADI20223665 A EC SENADI20223665A EC DI202203665 A ECDI202203665 A EC DI202203665A EC SP22003665 A ECSP22003665 A EC SP22003665A
Authority
EC
Ecuador
Prior art keywords
imidazo
toll
receptor agonists
pyridine derivatives
compounds
Prior art date
Application number
ECSENADI20223665A
Other languages
English (en)
Inventor
Lei Zhang
Jun Xiao
Omar Ahmad
Erik Alphie Lachapelle
Ethan Lawrence Fisher
Rayomand J Unwalla
Andrew Fensome
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP22003665A publication Critical patent/ECSP22003665A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos imidazo-piridinilo, o una sal de estos aceptable desde el punto de vista farmacéutico, a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a métodos y usos de dichos compuestos, sales y composiciones para el tratamiento de crecimiento celular anormal, que incluye cáncer, en un sujeto que lo necesita.
ECSENADI20223665A 2019-07-17 2022-01-17 Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll ECSP22003665A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875465P 2019-07-17 2019-07-17
US202062961288P 2020-01-15 2020-01-15

Publications (1)

Publication Number Publication Date
ECSP22003665A true ECSP22003665A (es) 2022-02-25

Family

ID=71728839

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20223665A ECSP22003665A (es) 2019-07-17 2022-01-17 Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll

Country Status (23)

Country Link
US (2) US11339159B2 (es)
EP (1) EP3999507B1 (es)
JP (1) JP7137733B2 (es)
KR (1) KR20220034862A (es)
CN (1) CN114364677B (es)
AU (1) AU2020315210B2 (es)
BR (1) BR112022000341A2 (es)
CA (1) CA3147266C (es)
CL (1) CL2022000032A1 (es)
CO (1) CO2022000259A2 (es)
CR (1) CR20220018A (es)
CU (1) CU20220003A7 (es)
EC (1) ECSP22003665A (es)
ES (1) ES3011282T3 (es)
IL (1) IL289877A (es)
MX (1) MX2022000656A (es)
PE (1) PE20220342A1 (es)
PH (1) PH12022550004A1 (es)
PY (1) PY2037133A (es)
TW (1) TWI755788B (es)
UY (1) UY38786A (es)
WO (1) WO2021009676A1 (es)
ZA (1) ZA202201330B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US11339159B2 (en) * 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2022153157A1 (en) 2021-01-13 2022-07-21 Pfizer Inc. A crystalline form of 2-((4-amino-2-(ethoxymethyl)-6,7-dimethyl-1 h-imidazo[4,5-c]pyridin-1-yl)methyl)-2-methylpropane-1,3-diol free base
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
EP4716685A1 (en) * 2023-05-22 2026-04-01 F. Hoffmann-La Roche AG Imidazo[4,5-c]pyridine compounds for the treatment of cancer
TW202515531A (zh) * 2023-07-07 2025-04-16 美商輝瑞股份有限公司 兩親性ｔｌｒ７／８佐劑及其用途
WO2025094035A1 (en) * 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔４，５−ｃ〕ピリジン−４−アミン
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US20070259881A1 (en) 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
HRP20120895T1 (hr) 2007-05-08 2012-11-30 Astrazeneca Ab Imidazokinolini sa imuno-modulacijskim svojstvima
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
CN104185477B (zh) 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
PT3134402T (pt) * 2014-04-22 2020-07-02 Hoffmann La Roche Compostos de 4-amino-imidazoquinolina
WO2016001810A1 (en) 2014-07-01 2016-01-07 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
SG11201704512PA (en) 2014-12-08 2017-07-28 Hoffmann La Roche 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
MX2018007319A (es) 2015-12-14 2018-09-06 Glaxosmithkline Biologicals Sa Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
US10533007B2 (en) * 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
EP3541219B1 (en) 2016-11-16 2024-01-24 Wink Robotics Eyelid covering and stabilization for automatic eyelash extension
CN108794467A (zh) * 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
US11339159B2 (en) * 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists

Also Published As

Publication number Publication date
CO2022000259A2 (es) 2022-01-17
CA3147266C (en) 2023-09-12
WO2021009676A8 (en) 2022-03-03
JP7137733B2 (ja) 2022-09-14
KR20220034862A (ko) 2022-03-18
US11339159B2 (en) 2022-05-24
CL2022000032A1 (es) 2022-09-02
MX2022000656A (es) 2022-02-16
UY38786A (es) 2021-02-26
PY2037133A (es) 2021-10-01
CA3147266A1 (en) 2021-01-21
EP3999507C0 (en) 2025-01-15
IL289877A (en) 2022-03-01
CN114364677B (zh) 2024-07-09
EP3999507A1 (en) 2022-05-25
AU2020315210A1 (en) 2022-02-03
AU2020315210B2 (en) 2023-01-12
EP3999507B1 (en) 2025-01-15
CR20220018A (es) 2022-02-08
TW202116770A (zh) 2021-05-01
TWI755788B (zh) 2022-02-21
WO2021009676A1 (en) 2021-01-21
CU20220003A7 (es) 2022-08-09
BR112022000341A2 (pt) 2022-04-12
US20210017172A1 (en) 2021-01-21
JP2022534125A (ja) 2022-07-27
PE20220342A1 (es) 2022-03-14
US11976064B2 (en) 2024-05-07
PH12022550004A1 (en) 2022-11-14
ES3011282T3 (en) 2025-04-07
US20220274986A1 (en) 2022-09-01
CN114364677A (zh) 2022-04-15
ZA202201330B (en) 2022-10-26

Similar Documents

Publication Publication Date Title
ECSP22003665A (es) Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll
DOP2020000191A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina
NI201800033A (es) Derivados de 8-[6-[3-(amino)propoxi]-3piridil]-1-isopropil-imidazo[4, 5-c]quinolin -2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer.
NI201900039A (es) Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer
DOP2021000154A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2
MX2022001908A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina.
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CO2021006114A2 (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
NI201900094A (es) COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
CO2017011969A2 (es) Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios